Three Drugs Given Together for Glioma That Came Back or Did Not Respond
Original title: Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so the drugs have been given to people before but are still being tested.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing whether three drugs given together can help people whose glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary came back or did not get better with earlier treatment.
Who this trial is for. This trial is for people with a glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary that did not respond to past treatment, or that came back after treatment. It tests three drugs given together: pembrolizumab, olaparib, and temozolomide.
Where it stands. This trial has not reported results. It is looking at how safe the three drugs are together, and how well they work. The answer is not in yet.
What this means, and what it doesn't
What it could mean: There is a study looking at this drug combination for gliomas that came back or did not respond. Someone in that situation could ask their care team about it. The care team can say whether it makes sense for them.
What it doesn't mean: This does not mean these drugs are known to work. A trial is a test, not a proven treatment. Joining a trial is not a guarantee that it will help. It is not a promise of a cure.
Source: ClinicalTrials.gov, July 22, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.